Drugs / Dendritic cells
Trials 18
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01171469 | Sep 2010 → May 2012 | anaplastic astrocytoma, ependymoma, glioblastoma, medulloblastoma | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT01149902 | Jul 2010 → Mar 2012 | head and neck cancer | University of Yamanashi | Unknown | No outcome recorded |
| Phase 1 | NCT00124124 | Jul 2005 → Jul 2008 | melanoma | Dr. Nina Bhardwaj | Completed | No outcome recorded |
| Phase 1/28 trials | ||||||
| Phase 1/2 | NCT06866158 | May → Aug 2024 overdue | diabetic kidney disease | PT. JES Kasih Nusantara Sejahterah | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02496520 | Sep 2014 → Sep 2018 | central nervous system neoplasm, sarcoma | Clinica Universidad de Navarra, Universidad de Navarra | Completed | No outcome recorded |
| Phase 1/2 | NCT03450044 | Jan 2014 → Jul 2018 | female breast carcinoma | Fundación Salud de los Andes | Completed | No outcome recorded |
| Phase 1/2 | NCT01235845 | Jan 2011 → Dec 2012 | malignant glioma | Qingdao University | Unknown | No outcome recorded |
| Phase 1/2 | NCT00961844 | Aug 2009 → Jun 2012 | metastatic melanoma | Steinar Aamdal | Terminated | No outcome recorded |
| Phase 1/2 | NCT01944709 | Aug 2006 → Dec 2007 | melanoma | Prof. Dr. Silke Gillessen | Terminated | No outcome recorded |
| Phase 1/2 | NCT00847106 | Mar 2004 → Oct 2005 | melanoma | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00795977 | Nov 2003 → Nov 2011 | malignant pancreatic neoplasm | Fukushima Medical University | Unknown | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT04184232 | Jul 2019 → Dec 2020 | urinary bladder cancer | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Completed | No outcome recorded |
| Phase 2 | NCT04212377 | Apr 2019 → Mar 2021 | endometrial cancer | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02669719 | Jan 2016 → Jan 2017 | non-small cell lung carcinoma | Shanghai Chest Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02487550 | Aug 2015 → Jul 2028 expected | kidney cancer | The First People's Hospital of Changzhou | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT01567202 | Mar 2012 → Nov 2020 | glioblastoma | Huashan Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT00610389 | Feb 2008 → Apr 2010 | hepatocellular carcinoma, melanoma, renal cell carcinoma | Clinica Universidad de Navarra, Universidad de Navarra | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02771301 | Feb 2016 → Jan 2019 | glioma | Hebei Yanda Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dendritic cells | “Eight to ten million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to...” NCT01567202 ↗17“Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.” NCT02487550 ↗ “In vitro generated dendritic cells are loaded with tumor derived peptides and injected subcutaneously.” NCT01944709 ↗ “Dendritic cells (DCs) are immune cells that form part of the mammalian immune system.” NCT01235845 ↗ “DCL (Dendritic Cells+Lymphocytes) previously matured with S-Protein of SARS-CoV-2.” NCT06866158 ↗ |
| Known as | DCs | “Eight to ten million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to...” NCT01567202 ↗ |
| Modality | Cell therapy | “0.5 to 3 x 106 DCs per peptide antigen (total not to exceed 18 x 106 cells) will be administered intradermally as per injection SOP.” NCT00124124 ↗ |
| Route | Other | “0.5 to 3 x 106 DCs per peptide antigen (total not to exceed 18 x 106 cells) will be administered intradermally as per injection SOP.” NCT00124124 ↗ |